KAKEN PHARMACEUTICAL CO.,LTD. [4521.T]
TOKYO, Mar 27 (Pulse News Wire) – Kaken Pharmaceutical CO.,LTD. (4521.T) announced today that its board of directors meeting held , resolved to make changes to its executive positions effective July 1, 2026.
All five internal directors and three external directors will continue their roles without any representative changes. Regarding the appointment of directors and auditors, a resolution is expected at the company's 106th regular shareholders' meeting scheduled for June 2026. Among the changes, tax accountant Masahiko Enomoto will join as an external auditor, replacing outgoing auditor Yoshiaki Matsumoto.
Additionally, Kazuhide Ishikuro will remain as a permanent auditor. Effective July 1, 2026, Nakazawa Noboru, currently the head of pharmaceutical sales department, will take up the position of executive officer. Other executives will retain their positions except for those mentioned.
🟡 Confidence: Standard AI-translated content.